Patents Assigned to Pentech Pharmaceuticals, Inc.
-
Patent number: 6660298Abstract: Method for preparing a wet granule formulation of paroxetine hydrochloride are disclosed. The formulations are suitable for tabletting and capsulation.Type: GrantFiled: July 27, 2000Date of Patent: December 9, 2003Assignee: Pentech Pharmaceuticals, Inc.Inventors: Bruce Ronsen, Venkata R. Kota, Yogesh Sadhale
-
Patent number: 6638948Abstract: A free-flowing, amorphous paroxetine hydrochloride composition suitable as a therapeutic agent for premature ejaculation can be prepared by dissolving paroxetine free base in a hydrochloric acid-ethanol solution followed by drying. The present compositions comprise amorphous paroxetine hydrochloride and at least one hydroxyl-bearing compound. In one preferred embodiment, the hydroxyl-bearing compound is ethanol and the amount of ethanol present in the amorphous product is in the range of 1 to 4 weight percent based on paroxetine hydrochloride. The amorphous product is stable and substantially non-hygroscopic.Type: GrantFiled: September 30, 1997Date of Patent: October 28, 2003Assignee: Pentech Pharmaceuticals, Inc.Inventors: Bruce Ronsen, Ragab El-Rashidy
-
Patent number: 6566368Abstract: Impotence can be ameliorated without substantial undesirable side effects by nasal administration of apomorphine, optionally with an antiemetic agent present in an amount sufficient to substantially reduce nausea symptoms that may be associated with the use of apomorphine.Type: GrantFiled: October 23, 2001Date of Patent: May 20, 2003Assignee: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Bruce Ronsen
-
Patent number: 6503927Abstract: A stable amorphous paroxetine hydrochloride composition suitable as a therapeutic agent is prepared employing an aqueous solvent medium containing an acidulant and polyvinylpyrrolidone and drying the resulting solid dispersion. The preferred compositions include amorphous paroxetine hydrochloride, polyvinylpyrrolidone and citric acid.Type: GrantFiled: October 28, 1999Date of Patent: January 7, 2003Assignee: Pentech Pharmaceuticals, Inc.Inventors: Bruce Ronsen, Yogesh D. Sadhale, Ragab El-Rashidy
-
Publication number: 20020035131Abstract: Male patients suffering from premature ejaculation dysfunction are treated by an oral therapy regimen of administration of paroxetine substantially within several hours before sexual intercourse. The beneficial effect of the paroxetine treatment can be optimized and maintained by a combination oral therapy regimen in which the patient converts to continual maintenance paroxetine administration after an initial loading period of daily doses of paroxetine taken over of relatively short duration.Type: ApplicationFiled: October 3, 2001Publication date: March 21, 2002Applicant: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Chris McMahon
-
Patent number: 6306437Abstract: Psychogenic impotence can be ameliorated without substantial undesirable side effects by administration of apomorphine and an antiemetic agent in an amount sufficient to substantially reduce nausea symptoms associated with the use of apomorphine.Type: GrantFiled: June 29, 2000Date of Patent: October 23, 2001Assignee: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Bruce Ronsen
-
Patent number: 6200983Abstract: Psychogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms so as to maintain a plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter.Type: GrantFiled: November 15, 1999Date of Patent: March 13, 2001Assignees: Pentech Pharmaceuticals, Inc., Queen's University at KingstonInventors: Ragab El-Rashidy, Jeremy P. W. Heaton, Alvaro Morales, Michael A. Adams
-
Patent number: 6193992Abstract: Sexual dysfunction in human females can be ameliorated, without substantial undesirable side effects, by apomorphine. Administration of apomorphine increases nerve stimulated clitoral intracavernosal blood flow and vaginal wall blood flow for enhanced clitoral erection and vaginal engorgement in a female. A plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter is preferably maintained.Type: GrantFiled: July 2, 1999Date of Patent: February 27, 2001Assignee: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Bruce Ronsen
-
Patent number: 6121276Abstract: Psychogenic impotence can be ameliorated without substantial undesirable side effects by administration of apomorphine and an antiemetic agent in an amount sufficient to substantially reduce nausea symptoms associated with the use of apomorphine.Type: GrantFiled: June 22, 1998Date of Patent: September 19, 2000Assignee: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Bruce Ronsen
-
Patent number: 6087362Abstract: The treatment of sexual dysfunction in human patients by an oral therapy regimen of administration of apomorphine and sildenafil is disclosed. This treatment optimizes the efficacy of each drug and substantially minimizes the undesirable side effects associated individually therewith. Apomorphine and sildenafil can be co-administered with a combination dosage unit or administered sequentially in separate dosage units, substantially prior to sexual activity. Other erectogenic agents can be administered along with apomorphine and sildenafil.Type: GrantFiled: March 16, 1999Date of Patent: July 11, 2000Assignee: Pentech Pharmaceuticals, Inc.Inventor: Ragab El-Rashidy
-
Patent number: 5994363Abstract: Symptoms of Parkinson's disease and psychogenic male erectile dysfunction (MED) can be ameliorated through the use of apomorphine. The adverse side effects of apomorphine administration, such as nausea, vomiting, yawning, and cardiovascular effects, can be significantly reduced by a dose escalating method of acclimatization. An initial dose of apomorphine is administered to the patient, and subsequently increased over a period of time until a final apomorphine dose in excess of a desired therapeutic dose has been received by the patient. Thereafter a therapeutic dose of apomorphine, less than the final apomorphine dose, is administered to the patient with attendant reduced side effects.Type: GrantFiled: August 24, 1998Date of Patent: November 30, 1999Assignee: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Bruce Ronsen
-
Patent number: 5985889Abstract: Psychogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms so as to maintain a plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter.Type: GrantFiled: June 22, 1998Date of Patent: November 16, 1999Assignees: Pentech Pharmaceuticals, Inc., Queen's University at KingstonInventors: Ragab El-Rashidy, Jeremy P. W. Heaton, Alvaro Morales, Michael A. Adams
-
Patent number: 5945117Abstract: Sexual dysfunction in human females can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms. Administration of apomorphine increases nerve stimulated clitoral intracavernosal blood flow and vaginal wall blood flow for enhanced clitoral erection and vaginal engorgement in a female. A plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter is preferably maintained.Type: GrantFiled: January 30, 1998Date of Patent: August 31, 1999Assignee: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Bruce Ronsen
-
Patent number: 5888534Abstract: A composition providing a relatively slow release of water-soluble drugs, such as apomorphine, for delivery via the sublingual or buccal routes.Type: GrantFiled: April 29, 1997Date of Patent: March 30, 1999Assignee: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Bruce Ronsen, Emad Eldin Hassan
-
Patent number: 5830500Abstract: A direct compression tablet exhibiting relatively low hardness provides a relatively rapid release of fluoxetine. The tablet has a hardness of no more than about 6 kilopascals and a dicalcium phosphate dihydrate-to-disintegrant weight ratio of about 3 to about 7.Type: GrantFiled: July 22, 1996Date of Patent: November 3, 1998Assignee: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Bruce Ronsen
-
Patent number: 5770606Abstract: Psychogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms so as to maintain a plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter.Type: GrantFiled: October 20, 1995Date of Patent: June 23, 1998Assignees: Pentech Pharmaceuticals, Inc., Queen's University at KingstonInventors: Ragab El-Rashidy, Jeremy P. W. Heaton, Alvaro Morales, Michael A. Adams
-
Patent number: 5672612Abstract: A free-flowing, amorphous paroxetine hydrochloride-ethanol composition suitable as a therapeutic agent for premature ejaculation can be prepared by dissolving paroxetine free base in a hydrochloric acid-ethanol solution followed by drying. In a preferred embodiment, the amount of ethanol present in the amorphous product is in the range of 1 to 4 weight percent based on paroxetine hydrochloride. The amorphous product is stable and substantially non-hygroscopic.Type: GrantFiled: September 9, 1996Date of Patent: September 30, 1997Assignee: Pentech Pharmaceuticals, Inc.Inventors: Bruce Ronsen, Ragab El-Rashidy
-
Patent number: 5624677Abstract: A composition providing a relatively slow release of water-soluble drugs, such as apomorphine, for delivery via the sublingual or buccal routes.Type: GrantFiled: June 13, 1995Date of Patent: April 29, 1997Assignee: Pentech Pharmaceuticals, Inc.Inventors: Ragab El-Rashidy, Bruce Ronsen, Emad E. Hassan
-
Patent number: 5562917Abstract: Dosage forms for the transdermal administration of apomorphine are described. The dosage forms are water-soluble gel compositions that contain apomorphine, optionally together with a permeation enhancer, or transdermal patches.Type: GrantFiled: December 23, 1994Date of Patent: October 8, 1996Assignee: Pentech Pharmaceuticals, Inc.Inventors: Franck Durif, Ragab El-Rashidy